At the end of each year, the pharmaceutical industry is always busy, especially in the context of the intensification of changes in the pharmaceutical market, many pharmaceutical companies are busy selling and adjusting their R&D pipelines to better cope with the challenges
.
For example, on November 17, Jingfeng Pharmaceutical announced that according to the needs of the company's business and strategic development, its wholly-owned subsidiary Shanghai Jingfeng Pharmaceutical Co.
, Ltd.
intends to sell its real estate located in Lane 868, Puming Road, Pudong New Area, Shanghai, with a total construction area of 701.
63 square meters, for 120 million yuan
.
The property consists of 463.
55 square meters in Building 23, 017 (119.
04 square meters) on the 1st basement floor of No.
24, and 018 (119.
04 square meters)
on the 1st basement floor.
Betta Pharmaceuticals said on the investor interactive platform on November 16 that the BPI-9016 project developed a c-Met inhibitor, based on existing clinical research data, the efficacy did not meet the expected target, and the company's development
has been suspended after comprehensive evaluation.
On November 15, Innovative Biopharma and Huang Pharma announced that the company is actively making a strategic shift to focus on drugs that are at the forefront of the internal pipeline and most likely to drive near-term value
.
It is reported that the Company will prioritize its late-stage registration studies and regulatory approvals for these drugs, some early-stage studies will no longer be prioritized for in-house development, and certain other projects will consider external business opportunities to allow the Company to focus its resources on
its late-stage drugs.
The Company will seek potential partners to commercialize its drugs outside of China to accelerate the delivery of innovative medicines
to patients worldwide.
On the same day, Harbour Biopharma announced that it intends to sell the production plant of the Biomacromolecule R&D Innovation Center Project for 146 million yuan, including machinery and equipment, various vehicles, tools and instruments, furniture, communication facilities and equipment, fixed fixtures in the leased premises (including equipment and facilities installed by the seller), office equipment and furniture related to the production plant, and certain transfers
of related agreements related to the production plant 。 It is worth mentioning that the company has taken several actions since November, such as on November 11, the company announced the sale of its wholly-owned subsidiary Nona Biologics' fully human heavy chain antibody platform HCAb to Moderna in the United States, according to the agreement, Moderna can obtain the global rights to multiple target sequences developed by the platform for the development of gene therapy, and is fully responsible for all subsequent
research and development, production and commercialization.
On November 14, CStone announced the suspension of production at its Suzhou production base, a rumor that has also attracted much attention in the industry recently
.
The company responded to the matter on November 15 on the official microblog, and said that this move is to reduce the operating costs of the enterprise, based on full research and discussion, after careful consideration and decision of the company, the Suzhou factory has temporarily stopped trial operation
in the first half of this month.
ST Guodan also recently announced that the company intends to sell part of its assets, API production workshop assets, to Jiangsu Yingke Biopharmaceutical Co.
, Ltd.
for 4 million yuan.
For this transaction, the company said that after the completion of this sale, it will be conducive to optimizing the company's asset structure
.
In the long term, reducing fixed costs and finance expenses has a positive impact
on the company's future financial position.
It can be seen that recently, pharmaceutical companies have sold products, technology, factories and real estate, and some have stopped production and adjusted their R&D
pipelines.
Behind the frequent actions of pharmaceutical companies, the transformation of the entire pharmaceutical market is also accelerating, and the industry expects that the relevant adjustment actions of pharmaceutical companies will continue in the future, especially for innovative pharmaceutical companies with large R&D investment, long payback period, high R&D risk, and commercial challenges, "broken wrists" or continuous
in the layout of product pipelines.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
